BG107529A - Карбаматни съединения за използване при профилактика или лечение на невропатична болка, мигренозна невралгия и болка свързана с мигрена - Google Patents

Карбаматни съединения за използване при профилактика или лечение на невропатична болка, мигренозна невралгия и болка свързана с мигрена Download PDF

Info

Publication number: BG107529A
Authority: BG; Bulgaria
Prior art keywords: formula; enantiomer; pain; enantiomers; free
Prior art date: 2000-07-21

Application number

BG107529A

Other languages

Bulgarian (bg)

English (en)

Inventor

Ellen Codd

Richard Shank

Katherine ROGERS

Carlos Plata-Salaman

Boyu Zhao

Original Assignee

Ortho-Mcneil Pharmaceutical, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-21

Filing date

2003-02-05

Publication date

2003-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22820176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG107529(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-05 Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.

2003-09-30 Publication of BG107529A publication Critical patent/BG107529A/bg

Links

208000004296 neuralgia Diseases 0.000 description 62
208000019695 Migraine disease Diseases 0.000 description 51
206010027599 migraine Diseases 0.000 description 50
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 45
208000002193 Pain Diseases 0.000 description 45
230000036407 pain Effects 0.000 description 44
239000000203 mixture Substances 0.000 description 39
208000021722 neuropathic pain Diseases 0.000 description 34
238000011282 treatment Methods 0.000 description 22
238000000034 method Methods 0.000 description 16
230000000694 effects Effects 0.000 description 15
239000008194 pharmaceutical composition Substances 0.000 description 15
241000700159 Rattus Species 0.000 description 14
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 14
230000002265 prevention Effects 0.000 description 13
210000002683 foot Anatomy 0.000 description 12
229910052739 hydrogen Inorganic materials 0.000 description 12
239000001257 hydrogen Substances 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
239000003937 drug carrier Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
150000001875 compounds Chemical class 0.000 description 7
239000003814 drug Substances 0.000 description 7
229910052736 halogen Inorganic materials 0.000 description 7
150000002367 halogens Chemical class 0.000 description 7
208000011580 syndromic disease Diseases 0.000 description 7
239000003826 tablet Substances 0.000 description 7
206010019233 Headaches Diseases 0.000 description 6
208000004454 Hyperalgesia Diseases 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
230000004044 response Effects 0.000 description 6
210000001032 spinal nerve Anatomy 0.000 description 6
125000001424 substituent group Chemical group 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
239000001961 anticonvulsive agent Substances 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
238000009472 formulation Methods 0.000 description 5
231100000869 headache Toxicity 0.000 description 5
210000005036 nerve Anatomy 0.000 description 5
201000001119 neuropathy Diseases 0.000 description 5
230000007823 neuropathy Effects 0.000 description 5
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
208000033808 peripheral neuropathy Diseases 0.000 description 5
-1 phenyl alkyl carbamate compounds Chemical class 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
208000000060 Migraine with aura Diseases 0.000 description 4
206010053552 allodynia Diseases 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
125000004093 cyano group Chemical group *C#N 0.000 description 4
238000011161 development Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
206010052787 migraine without aura Diseases 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000007909 solid dosage form Substances 0.000 description 4
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
206010001497 Agitation Diseases 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
239000002775 capsule Substances 0.000 description 3
150000004657 carbamic acid derivatives Chemical class 0.000 description 3
BQYRVMAWJCIIKI-UHFFFAOYSA-N carbamic acid;1-phenylethane-1,2-diol Chemical class NC(O)=O.OCC(O)C1=CC=CC=C1 BQYRVMAWJCIIKI-UHFFFAOYSA-N 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
239000011630 iodine Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
229960005181 morphine Drugs 0.000 description 3
230000002981 neuropathic effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000008035 Back Pain Diseases 0.000 description 2
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
208000032131 Diabetic Neuropathies Diseases 0.000 description 2
208000001640 Fibromyalgia Diseases 0.000 description 2
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010027910 Mononeuritis Diseases 0.000 description 2
206010028836 Neck pain Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
208000004983 Phantom Limb Diseases 0.000 description 2
206010056238 Phantom pain Diseases 0.000 description 2
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
230000003556 anti-epileptic effect Effects 0.000 description 2
229960003965 antiepileptics Drugs 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000001914 calming effect Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000007894 caplet Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000008859 change Effects 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000007897 gelcap Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
150000002431 hydrogen Chemical class 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
208000013734 mononeuritis simplex Diseases 0.000 description 2
201000005518 mononeuropathy Diseases 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
230000001953 sensory effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
208000020431 spinal cord injury Diseases 0.000 description 2
239000007921 spray Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
206010003791 Aura Diseases 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010015958 Eye pain Diseases 0.000 description 1
208000001375 Facial Neuralgia Diseases 0.000 description 1
206010016059 Facial pain Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
206010061296 Motor dysfunction Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
206010034960 Photophobia Diseases 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
206010054874 Sphenopalatine neuralgia Diseases 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000003255 drug test Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012054 flavored emulsion Substances 0.000 description 1
235000020375 flavoured syrup Nutrition 0.000 description 1
239000008394 flocculating agent Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000003371 gabaergic effect Effects 0.000 description 1
229960002870 gabapentin Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000000575 glycinergic effect Effects 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
238000007726 management method Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000002357 osmotic agent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
230000001314 paroxysmal effect Effects 0.000 description 1
235000021400 peanut butter Nutrition 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000009984 peri-natal effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
OANVFVBYPNXRLD-UHFFFAOYSA-M propyromazine bromide Chemical compound [Br-].C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)C(C)[N+]1(C)CCCC1 OANVFVBYPNXRLD-UHFFFAOYSA-M 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
239000000565 sealant Substances 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000003238 somatosensory effect Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
229950010357 tetrodotoxin Drugs 0.000 description 1
CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940102566 valproate Drugs 0.000 description 1
210000000857 visual cortex Anatomy 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BG107529A 2000-07-21 2003-02-05 Карбаматни съединения за използване при профилактика или лечение на невропатична болка, мигренозна невралгия и болка свързана с мигрена BG107529A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21965700P	2000-07-21	2000-07-21
PCT/US2001/022322 WO2002007822A2 (en)	2000-07-21	2001-07-16	Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain

Publications (1)

Publication Number	Publication Date
BG107529A true BG107529A (bg)	2003-09-30

Family

ID=22820176

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107529A BG107529A (bg)	2000-07-21	2003-02-05	Карбаматни съединения за използване при профилактика или лечение на невропатична болка, мигренозна невралгия и болка свързана с мигрена

Country Status (28)

Country	Link
US (4)	US20020107283A1 (de)
EP (1)	EP1305082B1 (de)
JP (1)	JP5271473B2 (de)
KR (1)	KR100792814B1 (de)
CN (1)	CN1250213C (de)
AT (1)	ATE267629T1 (de)
AU (2)	AU7349301A (de)
BG (1)	BG107529A (de)
BR (1)	BR0112713A (de)
CA (1)	CA2416819C (de)
CZ (1)	CZ2003445A3 (de)
DE (1)	DE60103546T2 (de)
DK (1)	DK1305082T3 (de)
EA (1)	EA005648B1 (de)
ES (1)	ES2221651T3 (de)
HU (1)	HUP0302940A3 (de)
IL (2)	IL154052A0 (de)
MX (1)	MXPA03000619A (de)
MY (1)	MY127317A (de)
NO (1)	NO330055B1 (de)
NZ (1)	NZ523851A (de)
PL (1)	PL365701A1 (de)
PT (1)	PT1305082E (de)
SK (1)	SK1962003A3 (de)
TR (1)	TR200401511T4 (de)
UA (1)	UA74195C2 (de)
WO (1)	WO2002007822A2 (de)
ZA (1)	ZA200301403B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6815464B2 (en) *	2001-02-27	2004-11-09	Ortho-Mcneil Pharmaceutical, Inc.	Carbamate compounds for use in the treatment of pain
PL368164A1 (en)	2001-07-16	2005-03-21	Ortho-Mcneil Pharmaceutical, Inc.	Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
DE60217493T2 (de) *	2001-07-16	2007-11-15	Ortho-Mcneil Pharmaceutical, Inc.	Verwendung von carbamat-verbindungen zur prävention oder behandlung von neuropathischen schmerzen und migräneartigen kopfschmerzen
US20040087642A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US7323443B2 (en) *	2002-12-12	2008-01-29	Agennix Inc.	Lactoferrin in the reduction of pain
US7183381B2 (en) *	2004-10-26	2007-02-27	Agennix, Inc.	Composition of lactoferrin related peptides and uses thereof
EP1850841A1 (de) *	2005-01-20	2007-11-07	Janssen Pharmaceutica N.V.	Verfahren zur qt-intervall-steuerung
MY148405A (en)	2006-03-30	2013-04-30	Glaxosmithkline Biolog Sa	Immunogenic composition
BRPI0717824A2 (pt) *	2006-10-10	2014-04-15	Janssen Pharmaceutica Nv	Cristal de carbamato de (s)-(+)-2-(2-clorofenil)-2-hidróxi-etila
US8609849B1 (en)	2010-11-30	2013-12-17	Fox Chase Chemical Diversity Center, Inc.	Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US20150057351A1 (en) *	2013-08-22	2015-02-26	Sucampo Ag	Method for treating neuropathic pain

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3278380A (en) *	1962-02-06	1966-10-11	Armour Pharma	Methods of calming employing diphenyl hydroxy carbamate compounds
US3265728A (en) *	1962-07-18	1966-08-09	Armour Pharma	Substituted phenethyl carbamates
HU191549B (en) *	1984-04-11	1987-03-30	Richter Gedeon Vegyeszet	Process for producing 1-/6-/2 comma above-substituted-5 comma above, 6 comma above, 7 comma above, 8 comma above-tetrahydro-4 comma above-oxo-quinazolino//-3,4-dihydro-6,7-disubstituted-isoquinoline derivatives
US4868190A (en) *	1988-12-27	1989-09-19	Hoechst-Roussel Pharmaceuticals, Inc.	N-pyridinyl-9H-carbazol-9-amines
GB9518027D0 (en) *	1995-09-05	1995-11-08	Wellcome Found	Pharmacologically active compound
US5698588A (en) *	1996-01-16	1997-12-16	Yukong Limited	Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
BR9810742A (pt) *	1997-06-05	2000-09-12	Sanofi Synthelabo	Derivados de 5-naftalen -1il-1,3-dioxana, preparação dos mesmos e aplicação em terapia
CZ20032300A3 (cs) *	2001-02-27	2005-01-12	Ortho-Mcneil Pharmaceutical, Inc.	Léčivo pro prevenci nebo léčbu bipolárních chorob
DE60216457T2 (de) *	2001-02-27	2007-09-20	Ortho-Mcneil Pharmaceutical, Inc.	Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
DE60221670T2 (de) *	2001-02-27	2008-04-30	Ortho-Mcneil Pharmaceutical, Inc.	Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen

2001
- 2001-07-16 WO PCT/US2001/022322 patent/WO2002007822A2/en not_active Ceased
- 2001-07-16 CZ CZ2003445A patent/CZ2003445A3/cs unknown
- 2001-07-16 JP JP2002513552A patent/JP5271473B2/ja not_active Expired - Lifetime
- 2001-07-16 DE DE60103546T patent/DE60103546T2/de not_active Expired - Lifetime
- 2001-07-16 PL PL01365701A patent/PL365701A1/xx not_active Application Discontinuation
- 2001-07-16 SK SK196-2003A patent/SK1962003A3/sk unknown
- 2001-07-16 DK DK01952773T patent/DK1305082T3/da active
- 2001-07-16 TR TR2004/01511T patent/TR200401511T4/xx unknown
- 2001-07-16 AU AU7349301A patent/AU7349301A/xx active Pending
- 2001-07-16 KR KR1020037000914A patent/KR100792814B1/ko not_active Expired - Lifetime
- 2001-07-16 NZ NZ523851A patent/NZ523851A/en unknown
- 2001-07-16 PT PT01952773T patent/PT1305082E/pt unknown
- 2001-07-16 MX MXPA03000619A patent/MXPA03000619A/es active IP Right Grant
- 2001-07-16 CA CA2416819A patent/CA2416819C/en not_active Expired - Fee Related
- 2001-07-16 IL IL15405201A patent/IL154052A0/xx unknown
- 2001-07-16 ES ES01952773T patent/ES2221651T3/es not_active Expired - Lifetime
- 2001-07-16 EA EA200300042A patent/EA005648B1/ru not_active IP Right Cessation
- 2001-07-16 BR BR0112713-6A patent/BR0112713A/pt not_active Application Discontinuation
- 2001-07-16 CN CNB01815798XA patent/CN1250213C/zh not_active Expired - Fee Related
- 2001-07-16 US US09/906,251 patent/US20020107283A1/en not_active Abandoned
- 2001-07-16 EP EP01952773A patent/EP1305082B1/de not_active Expired - Lifetime
- 2001-07-16 HU HU0302940A patent/HUP0302940A3/hu unknown
- 2001-07-16 UA UA2003010559A patent/UA74195C2/uk unknown
- 2001-07-16 AU AU2001273493A patent/AU2001273493B2/en not_active Ceased
- 2001-07-16 AT AT01952773T patent/ATE267629T1/de not_active IP Right Cessation
- 2001-07-20 MY MYPI20013443 patent/MY127317A/en unknown
2003
- 2003-01-20 NO NO20030299A patent/NO330055B1/no not_active IP Right Cessation
- 2003-01-20 IL IL154052A patent/IL154052A/en unknown
- 2003-02-05 BG BG107529A patent/BG107529A/bg unknown
- 2003-02-20 ZA ZA200301403A patent/ZA200301403B/en unknown
2004
- 2004-06-15 US US10/868,633 patent/US20040266866A1/en not_active Abandoned
2005
- 2005-02-18 US US11/194,876 patent/US20060183795A1/en not_active Abandoned
2009
- 2009-07-20 US US12/505,765 patent/US20090281179A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MY127317A (en)	2006-11-30
EP1305082B1 (de)	2004-05-26
PL365701A1 (en)	2005-01-10
NZ523851A (en)	2004-09-24
KR20030022300A (ko)	2003-03-15
ES2221651T3 (es)	2005-01-01
NO330055B1 (no)	2011-02-14
EP1305082A2 (de)	2003-05-02
CN1458853A (zh)	2003-11-26
US20020107283A1 (en)	2002-08-08
IL154052A0 (en)	2003-07-31
CN1250213C (zh)	2006-04-12
WO2002007822A2 (en)	2002-01-31
EA200300042A1 (ru)	2003-06-26
MXPA03000619A (es)	2004-07-30
JP5271473B2 (ja)	2013-08-21
ZA200301403B (en)	2004-06-15
HUP0302940A2 (hu)	2003-12-29
WO2002007822A3 (en)	2002-05-30
NO20030299L (no)	2003-03-12
CA2416819A1 (en)	2002-01-31
JP2004504362A (ja)	2004-02-12
DE60103546T2 (de)	2005-06-09
HUP0302940A3 (en)	2012-02-28
NO20030299D0 (no)	2003-01-20
DK1305082T3 (da)	2004-09-13
PT1305082E (pt)	2004-09-30
EA005648B1 (ru)	2005-04-28
AU2001273493B2 (en)	2005-08-11
BR0112713A (pt)	2003-07-22
US20040266866A1 (en)	2004-12-30
US20060183795A1 (en)	2006-08-17
ATE267629T1 (de)	2004-06-15
KR100792814B1 (ko)	2008-01-14
IL154052A (en)	2008-07-08
CZ2003445A3 (cs)	2004-08-18
US20090281179A1 (en)	2009-11-12
SK1962003A3 (en)	2004-08-03
TR200401511T4 (tr)	2004-08-23
AU7349301A (en)	2002-02-05
UA74195C2 (uk)	2005-11-15
CA2416819C (en)	2011-03-22
DE60103546D1 (de)	2004-07-01

Publication	Publication Date	Title
US20090281179A1 (en)	2009-11-12	Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache associated pain
AU2001273493A1 (en)	2002-05-02	Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
RU2303445C2 (ru)	2007-07-27	Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
RU2299729C2 (ru)	2007-05-27	Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
AU2002322442A1 (en)	2003-05-22	Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
ZA200401156B (en)	2005-06-22	Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain.
HK1063435B (en)	2010-01-22	Carbamate compounds for use in preventing or treating neuropathic pain